Second-line chemotherapy of platinum compound plus CPT-11 following ADOC chemotherapy in advanced thymic carcinoma: Analysis of seven cases

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 3005-3008

  Kanda, Shintaro ^a   Koizumi, Tomonobu ^a   Komatsu, Yoshimichi ^a   Yoshikawa, Sumiko ^a   Okada, Mitsuyo ^a   Hatayama, Orie ^a   Yasuo, Masanori ^a   Tsushima, Kenji ^a   Urushihata, Kazuhisa ^a   Kubo, Keishi ^a   Sasabayashi, Mari ^a   Takamizawa, Akemi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; Irinotecan; Salvage chemotherapy; Thymic malignancy

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IRINOTECAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; THYMUS CANCER; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYMUS NEOPLASMS; VINCRISTINE;

EID: 34547798083     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Levine GD and Rosai J: Thymic hyperplasia and neoplasia.: a review of current concepts. Hum Pathol 9: 495-515,1978.
2. Wick MR, Weiland LH, Scheithauer BW and Bernatz PE: Primary thymic carcinoma. Am J Surg Pathol 6: 613-630, 1982.
3. Shimosato Y, Kameya T, Nagai K and Suemasu K: Squamous cell carcinoma of the thymus: An analysis of eight cases. Am J Surg Pathol 1: 109-121, 1997.
4. Suster S and Rosai J: Thymic carcinoma. A clinicopathologic study of 60 cases. Cancer 67: 1025-1032, 1991.
5. Weide LG, Ulbright TM, Loehrer PJ and Williams SD: Thymic carcinoma. A distinct clinical entity responsive to chemotherapy. Cancer 71: 1219-1223, 1993.
6. Truong LD, Mody DR, Cagle PT, Jackson-York GL, Schwartz MR and Wheeler TM: Thymic carcinoma. A clinicopathologic study of 13 cases. Am J Surg Pathol 14: 151-166, 1990.
7. Yoh K,Goto KJshii G, Niho S, Ohmatsu H, Kubota K, Kakinuma R, Nagai K, Suga M and Nishiwaki Y: Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Cancer 98: 926-931, 2004.
8. Kitami A, Suzuki T, Kamio Y and Suzuki S: Chemotherapy of thymic carcinoma: analysis of seven cases and review of the literature. Jpn J Clin Oncol 31: 601-604, 2001.
9. Koizumi T, Takabayashi Y, Yamagishi S, Tsushima K, Takamizawa A, Tsukadaira A, Yamamoto H, Yamazaki Y, Yamaguchi S, Fujimoto K, Kubo K, Hirose Y, Hirayama J and Saegusa H: Chemotherapy for advanced thymic carcinoma Clinical responsive for cisplatin, doxorubicin, vincristine and cyclophosphamide (ADOC chemotherapy). Am J Clin Oncol 25: 266-268, 2002.
10. Greene MA and Malias MA: Aggressive multimodality treatment of invasive thymic carcinoma. J Thorac Cardiovasc Surg 125: 434-436, 2003.
11. Morio A, Nakahara K, Ohse Y, Tahara M, Goto T, Yakumaru K and Korenaga T: Efficacy of induction chemoradiotherapy in thymic cancer: report of a successful case and review of the literature. Int J Clin Oncol 7: 201-204, 2002.
12. Masaoka A, Monden Y, Nakahara K and Tanioka T: Follow-up study of thymomas with special reference to their clinical stages. Cancer 48: 2485-2492, 1981.
13. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.
14. National Cancer Institute: Common Toxicity Criteria (CTC) v 2.0. http://ctep.cancer.gov/reporting/ctc.html
15. Kelly K: Current role of irinotecan in the treatment of non-small cell lung cancer. Oncology (Williston Park) 16: 1153-1162, 2002.
16. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K,Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka M: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18: 317-323, 2007.
17. Noda K,Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; Japan Clinical Oncology Group: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346: 85-91, 2002.
18. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR and Gralla R: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small cell lung cancer. J Clin Oncol 17: 658-667, 1999.